CD8A and neoplasm: Taking together, the combination therapy of QTPlus‐AM21 and ATZ was able to significantly increase M1/M2 and CD8 T/Tregs ratios and increase CD11b+ Gr‐1+ MDSCs and NK1.1+ NK cells population in TME from MC38 tumor‐bearing mice (Figure 12).